Drugs / CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

Follow last change Apr 2023 re-read 3 minutes ago

CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

Developed for: B-cell non-Hodgkin lymphoma
Investigated by: Bioray Laboratories · Chinese Academy of Medical Sciences · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Zhejiang University

today NCT05741359 · Ph 1

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05741359	Apr 2023 → Nov 2026 expected	B-cell non-Hodgkin lymphoma	Bioray Laboratories	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05741359 ↗
Modality	Cell therapy	“CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection” NCT05741359 ↗
Target	CD19	“CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection” NCT05741359 ↗